August 20, 2024 02:45 PM EDT

J&J scores approval for Rybrevant combo in first-line lung cancer, stoking rivalry with Tagrisso

Nicole DeFeudis

Editor

Johnson & Johnson scored a label expansion for Rybrevant in combination with the newly-approved Lazcluze to treat certain first-line lung cancer patients, putting it in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J scores approval for Rybrevant combo in first-line lung cancer, stoking rivalry with Tagrisso

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Moderna plans $1.1B in R&D and program cuts, delays break-even point to 2028

Sanofi buys into radiopharmaceutical field with $110M upfront, going after space held by Novartis

A new startup wants to fight cancer with 'off-the-shelf' gene therapy, securing $26M seed round

Sofinnova’s Jim Healy on ‘more rational market’ as four biotech startups near their IPOs

J&J expands Tremfya into IBD with new FDA approval

Fulcrum's Phase 3 for old GSK drug fails, stock sinks

J&J scores ap­proval for Ry­bre­vant com­bo in first-line lung can­cer, stok­ing ri­val­ry with Tagris­so

Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

J&J scores approval for Rybrevant combo in first-line lung cancer, stoking rivalry with Tagrisso